Unraveling the Specific Recognition Between PD-L1 and Engineered CLP002 Functionalized Gold Nanostructures: MD Simulation Studies
Molecules · 2025
DOI: 10.3390/molecules30092045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Micaela Giannetti und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Science and Technologies, University of Rome "Tor Vergata", Via della Ricerca Scientifica, 00133 Rome, Italy. Hauptthemen laut MEDLINE: B7-H1 Antigen, Gold, Molecular Dynamics Simulation, Peptides. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
PD-L1 (programmed cell death ligand-1) is a protein located on the surface of regulatory cells. It has an immunosuppressive role as it binds specifically to the protein programmed cell death-1 (PD-1), a checkpoint glycoprotein, present on the surface of immune cells such as T and B lymphocytes. Many tumor cells block the immune response by overexpressing PD-L1 on their surface; therefore, targeting PD-L1 represents a powerful strategy that allows tumor localization. To determine the presence of PD-L1 in cells, the use of ad hoc functionalized peptides that bind to PD-L1 can be exploited. One of them is the peptide CLP002 (Trp-His-Arg-Ser-Tyr-Tyr-Thr-Trp-Asn-Leu-Asn-Thr), which, bound to surface-enhanced Raman scattering (SERS) gold nanostructures via a suitable linker, was shown to be highly effective in recognizing MDA-MB-231 breast cancer cells and, importantly, this recognition can be measured by SERS experiments. To characterize, on a molecular scale, the interaction between PD-L1 and peptide functionalized nanostructures, we performed molecular dynamics (MDs) simulations, studying the features of peptide monolayers bound on gold surfaces in the absence and presence of PD-L1. The results obtained allow us to explain why the nature of the linker plays a fundamental role in the binding and why a peptide carrying the same amino acids as CPL002 but with a different sequence (scrambled) is much less active than CLP002. These results open the way to an in silico evaluation of the key parameters that regulate the binding of PD-L1 useful for cancer recognition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical Science and Technologies, University of Rome "Tor Vergata", Via della Ricerca Scientifica, 00133 Rome, Italy.
- Department of Chemical Sciences, University of Padova, Via F. Marzolo 1, 35131 Padova, Italy.
- Pathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Via F. Gallini 2, 33081 Aviano, Italy.
- Pathology Unit, Department of Molecular Sciences and Nanosystems, Ca' Foscari University of Venice, Via Torino 155, 30172 Venice, Italy.
ORCID-Profile: Marina Gobbo, Lucio Litti, Flavio Rizzolio, Moreno Meneghetti, Claudia Mazzuca, Antonio Palleschi
Zitieren
APA
Giannetti, M., Gobbo, M., Litti, L., Caligiuri, I., Rizzolio, F., Meneghetti, M., Mazzuca, C., & Palleschi, A. (2025). Unraveling the Specific Recognition Between PD-L1 and Engineered CLP002 Functionalized Gold Nanostructures: MD Simulation Studies. Molecules. https://doi.org/10.3390/molecules30092045
Vancouver
Giannetti M, Gobbo M, Litti L, Caligiuri I, Rizzolio F, Meneghetti M, et al. Unraveling the Specific Recognition Between PD-L1 and Engineered CLP002 Functionalized Gold Nanostructures: MD Simulation Studies. Molecules. 2025. doi:10.3390/molecules30092045
BibTeX
@article{Giannetti2025,
author = {Giannetti, Micaela and Gobbo, Marina and Litti, Lucio and Caligiuri, Isabella and Rizzolio, Flavio and Meneghetti, Moreno and Mazzuca, Claudia and Palleschi, Antonio},
title = {Unraveling the Specific Recognition Between PD-L1 and Engineered CLP002 Functionalized Gold Nanostructures: MD Simulation Studies},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30092045}
}
EUVIMED